Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder.
Effects of clorgyline on urinary excretion of norepinephrine, dopamine, tyramine, and their major metabolites, 5-hydroxyindoleacetic acid and phenylethylamine, were studied in four women who suffered from primary, bipolar affective disorder. All patients had rapid mood cycles and were nonresponsive to lithium carbonate. During placebo administration, a strong correlation was found between the excretion rates of norepinephrine and dopamine and their respective metabolites. Clorgyline, 5 to 10 mg every or every other day, reduced overall-body norepinephrine turnover by 55% and increased tyramine but did not alter 5-hydroxyindoleacetic acid, phenylethylamine, or p-hydroxyphenylacetic acid excretion. These findings demonstrate the clinical actions of low-dose clorgyline and clorgyline's specificity as a monoamine oxidase A (MAO-A) inhibitor in vivo in humans, as well as the effects of specific MAO-A inhibition on monoamine metabolism.
D001714:Bipolar Disorder / Q000188:drug therapy / Q000523:psychology / Q000652:urine*; D002940:Circadian Rhythm; D003010:Clorgyline / Q000494:pharmacology* / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism / Q000652:urine*; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000378:metabolism / Q000652:urine*; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D008094:Lithium / Q000494:pharmacology / Q000627:therapeutic use; D016651:Lithium Carbonate; D010627:Phenethylamines / Q000652:urine; D010919:Placebos; D011437:Propylamines / Q000494:pharmacology*; D014439:Tyramine / Q000378:metabolism / Q000652:urine*
D010627:Phenethylamines; D010919:Placebos; D011437:Propylamines; D016651:Lithium Carbonate; D006897:Hydroxyindoleacetic Acid; D008094:Lithium; D003010:Clorgyline; D004298:Dopamine; D014439:Tyramine; D004837:Epinephrine